Literature DB >> 18973845

FibroMeters: a family of blood tests for liver fibrosis.

P Calès1, J Boursier, F Oberti, I Hubert, Y Gallois, M-C Rousselet, N Dib, V Moal, L Macchi, A Chevailler, S Michalak, G Hunault, J Chaigneau, A Sawadogo, F Lunel.   

Abstract

FibroMeters are blood tests for liver fibrosis with several specificities: two main diagnostic targets (fibrosis stage and area of fibrosis); adaptation to specific causes; and results confirmed by an expert system. Thus, FibroMeters comprise six different tests: one for staging and one for quantitation of liver fibrosis in each of the three main causes of chronic liver disease-chronic viral hepatitis, alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). FibroMeters display a high overall diagnostic accuracy and are the only tests to correctly classify 100% of HCV patients without fibrosis or with cirrhosis. They have 90% predictive values in a higher proportion of patients than with other usual blood tests. A 90% correct classification is available in 100% of HCV patients with the following reliable diagnostic intervals: F0/1, F1/2, F2+/-1, F3+/-1. In real-life conditions, the reproducibility of FibroMeters is higher than that of liver biopsy or ultrasonographic elastometry. FibroMeters are robust tests with the most stable diagnostic performance across different centers. Optional tests are also available, such as a specific one for cirrhosis, which has a diagnostic accuracy of 93.0% (AUROC: 0.92) and a 100% positive predictive value for diagnosis of HCV cirrhosis. Determination by FibroMeters of the area of fibrosis - the only direct, non-invasive, quantitative measurement of liver fibrosis - are especially useful for following-up cirrhosis as it correlates well with clinical events. FibroMeters are also very accurate in HVB or HIV-HCV co-infected patients. The tests specific for ALD and NAFLD also have a high diagnostic accuracy (AUROCs: 0.96 and 0.94, respectively, for significant fibrosis).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973845     DOI: 10.1016/S0399-8320(08)73992-7

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  20 in total

Review 1.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 2.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

Review 3.  Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.

Authors:  Dharmesh H Kaswala; Michelle Lai; Nezam H Afdhal
Journal:  Dig Dis Sci       Date:  2016-03-26       Impact factor: 3.199

Review 4.  Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

Authors:  Rosa Lombardi; Elena Buzzetti; Davide Roccarina; Emmanuel A Tsochatzis
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 5.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 6.  Role of liver biopsy in the era of direct-acting antivirals.

Authors:  Humberto C Gonzalez; Syed Mohammed Jafri; Stuart C Gordon
Journal:  Curr Gastroenterol Rep       Date:  2013-02

7.  The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D.

Authors:  Ben L Da; Pallavi Surana; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Antiviral Res       Date:  2019-12-16       Impact factor: 5.970

8.  Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study.

Authors:  Sheng-Di Wu; Ji-Yao Wang; Lei Li
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

Review 9.  Non-invasive markers for hepatic fibrosis.

Authors:  Ancha Baranova; Priyanka Lal; Aybike Birerdinc; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2011-08-17       Impact factor: 3.067

10.  Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India.

Authors:  Parikh Pathik; Surude Ravindra; Choksey Ajay; Bhate Prasad; Patel Jatin; Sawant Prabha
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.